FDA Evaluates Seven Unapproved Peptides for Potential Use

The Food and Drug Administration (FDA) is evaluating seven unapproved peptide substances due to their rising popularity for potential health benefits. This examination is taking place during meetings on July 23 and 24 at the FDA’s White Oak Campus in Silver Spring, Maryland. The FDA’s Pharmacy Compounding Advisory Committee is considering whether to recommend adding these peptides to the 503A Bulks List. Such an addition would allow their use in specific compounded prescription drugs. Despite the lack of FDA approval, these peptides are currently accessible via wellness clinics, compounding labs, and online sellers operating on the gray market.

Understanding Peptides

Peptides have gained attention for various applications, including weight loss, muscle building, performance enhancement, and chronic disease management. They are increasingly popular for wound repair as well. However, FDA reviewers have expressed concerns about the limited evidence backing the safety and effectiveness of the peptides in question. Meanwhile, HHS Secretary Robert F. Kennedy Jr. has shown support for expanding access to these peptide therapies.

Despite uncertain outcomes from the FDA meetings, consumer interest, as reported by Reuters, is likely to persist due to the alluring benefits linked with peptides.

Review of Specific Peptides

FDA documents highlight the seven peptides being reviewed, each with different proposed uses and forms:

• BPC-157: Proposed for ulcerative colitis; available in oral capsules, nasal spray, injections, transdermal cream, and rectal suppository formats.
• TB-500: Intended for wound healing; administered through subcutaneous or intramuscular injections.
• KPV: Used for wound healing and inflammatory conditions; comes in cream and gel forms.
• MOTS-c: Designed for obesity and osteoporosis; delivered via subcutaneous injection.
• Semax: Addresses cerebral ischemia, migraines, and trigeminal neuralgia; provided as an intranasal spray or subcutaneous injection.
• Emideltide: Targets opioid withdrawal, chronic insomnia, and narcolepsy; available as a subcutaneous injection.
• Epitalon: Used for managing insomnia; administered through subcutaneous injection.

Expert Testimonies and Concerns

Dr. Alex Tatem, a performance medicine and peptide expert, will testify at the FDA hearings. He has noted that BPC-157 and TB-500 are particularly promising for healing after injuries. Tatem emphasizes the safety of peptides, comparing them favorably to over-the-counter medications like ibuprofen, which carries risks of stomach bleeding and kidney damage according to FDA warnings. Millions of BPC-157 doses have been administered with minimal adverse events reported, Tatem states.

Nevertheless, the FDA remains cautious, pointing out the need for more human clinical trials to assess these peptides’ safety and efficacy. Dr. Marc Siegel, a Fox News senior medical analyst, stresses that while some peptides might be beneficial, others require more research to assess safety, particularly concerning potential kidney effects.

Future Proceedings

The outcome of the FDA hearings is highly anticipated. Even if the committee recommends inclusion of the peptides on the 503A Bulks List, the FDA must still complete its review and rulemaking process. Tatem is hopeful about the potential for patients to eventually access prescriptions for these peptides through medical supervision, including telehealth services.

He urges individuals to express their opinions to local representatives, advocating for access to safe, regulated peptides manufactured in the United States. This ongoing process highlights the significance of public engagement in healthcare decisions.